Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Han (Ann Arbour, MI, United States of America), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, AL, United States of America), D. Halpin (Exeter, United Kingdom), C. Jones (Research Triangle Park, NC, United States of America), S. Kilbride (Stockley Park, United Kingdom), P. Lange (Copenhagen, Denmark), D. Lomas (London, United Kingdom), F. Martinez (New York, NY, United States of America), H. Quasny (Research Triangle Park, NC, United States of America), D. Singh (Manchester, United Kingdom), R. Wise (Baltimore, MD, United States of America), D. Lipson (Collegeville and Philadelphia, United States of America). The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints. 2483

Member's Comments

No comment yet.

Related content which might interest you: The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Late Breaking Abstract - Real-world evidence of dual bronchodilator therapy using Clinical COPD Questionnaire in 4700 COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Late Breaking Abstract - Effects of long-term Tobramycin Inhalation Solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. The BATTLE Randomized Controlled Trial Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020 Evaluating cardiac safety of tiotropium in patients with COPD: Combined analysis of Holter-ECG data from four trials Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Triple therapy in COPD: Oportunities and challenges Source: Short Video Statement 2020 Year: 2020 Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Clinical predictors for long-term benefit of cetuximab maintenance therapy – Single center subanalysis of the GEMTAX IV trial Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020